Raised $125M Series B (Jun 2025). First human cataract trials launching 2026. Oryom robot designed to reach any point within the eye.
ForSight Robotics is developing the Oryom — a surgical robot designed to reach any anatomical point within the human eye, enabling robotic cataract surgery, retinal procedures, and glaucoma interventions with precision exceeding human capability. The company raised $125 million in Series B financing in June 2025 and is launching its first human cataract trials in 2026, making it one of the most clinically advanced ophthalmic robotics companies globally. If the 2026 trial results are positive, an FDA submission pathway follows for the world's first robotic eye surgery system at clinical scale.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.